2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice. / Andersen, Charlotte; Schjoldager, Janne Gram; Tortzen, Christian; Vegge, Andreas; Hufeldt, Majbritt Ravn; Skaanild, Mette Tingleff; Vogensen, Finn Kvist; Kristiansen, Karsten; Hansen, Axel Jacob Kornerup; Nielsen, John.

I: Journal of Biomedicine and Biotechnology, Bind 2013, 926942, 2013.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Andersen, C, Schjoldager, JG, Tortzen, C, Vegge, A, Hufeldt, MR, Skaanild, MT, Vogensen, FK, Kristiansen, K, Hansen, AJK & Nielsen, J 2013, '2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice', Journal of Biomedicine and Biotechnology, bind 2013, 926942. https://doi.org/10.1155/2013/926942

APA

Andersen, C., Schjoldager, J. G., Tortzen, C., Vegge, A., Hufeldt, M. R., Skaanild, M. T., ... Nielsen, J. (2013). 2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice. Journal of Biomedicine and Biotechnology, 2013, [926942]. https://doi.org/10.1155/2013/926942

Vancouver

Andersen C, Schjoldager JG, Tortzen C, Vegge A, Hufeldt MR, Skaanild MT o.a. 2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice. Journal of Biomedicine and Biotechnology. 2013;2013. 926942. https://doi.org/10.1155/2013/926942

Author

Andersen, Charlotte ; Schjoldager, Janne Gram ; Tortzen, Christian ; Vegge, Andreas ; Hufeldt, Majbritt Ravn ; Skaanild, Mette Tingleff ; Vogensen, Finn Kvist ; Kristiansen, Karsten ; Hansen, Axel Jacob Kornerup ; Nielsen, John. / 2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice. I: Journal of Biomedicine and Biotechnology. 2013 ; Bind 2013.

Bibtex

@article{c7581168f9f1480bb03e72ab4794e956,
title = "2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice",
abstract = "Consumption of isoflavones may prevent adiposity, hepatic steatosis, and dyslipidaemia. However, studies in the area are few and primarily with genistein. This study investigated the effects of formononetin and its synthetic analogue, 2-heptyl-formononetin (C7F), on lipid and cholesterol metabolism in C57BL/6J mice. The mice were fed a cholesterol-enriched diet for five weeks to induce hypercholesterolemia and were then fed either the cholesterol-enriched diet or the cholesterol-enriched diet-supplemented formononetin or C7F for three weeks. Body weight and composition, glucose homeostasis, and plasma lipids were compared. In another experiment, mice were fed the above diets for five weeks, and hepatic triglyceride accumulation and gene expression and histology of adipose tissue and liver were examined. Supplementation with C7F increased plasma HDL-cholesterol thereby increasing the plasma level of total cholesterol. Supplementation with formononetin did not affect plasma cholesterol but increased plasma triglycerides levels. Supplementation with formononetin and C7F induced hepatic steatosis. However, formononetin decreased markers of inflammation and liver injury. The development of hepatic steatosis was associated with deregulated expression of hepatic genes involved in lipid and lipoprotein metabolism. In conclusion, supplementation with formononetin and C7F to a cholesterol-enriched diet adversely affected lipid and lipoprotein metabolism in C57BL/6J mice.",
author = "Charlotte Andersen and Schjoldager, {Janne Gram} and Christian Tortzen and Andreas Vegge and Hufeldt, {Majbritt Ravn} and Skaanild, {Mette Tingleff} and Vogensen, {Finn Kvist} and Karsten Kristiansen and Hansen, {Axel Jacob Kornerup} and John Nielsen",
note = "BioMed Research International (formerly titled Journal of Biomedicine and Biotechnology)",
year = "2013",
doi = "10.1155/2013/926942",
language = "English",
volume = "2013",
journal = "Journal of Biomedicine and Biotechnology",
issn = "1110-7243",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - 2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice

AU - Andersen, Charlotte

AU - Schjoldager, Janne Gram

AU - Tortzen, Christian

AU - Vegge, Andreas

AU - Hufeldt, Majbritt Ravn

AU - Skaanild, Mette Tingleff

AU - Vogensen, Finn Kvist

AU - Kristiansen, Karsten

AU - Hansen, Axel Jacob Kornerup

AU - Nielsen, John

N1 - BioMed Research International (formerly titled Journal of Biomedicine and Biotechnology)

PY - 2013

Y1 - 2013

N2 - Consumption of isoflavones may prevent adiposity, hepatic steatosis, and dyslipidaemia. However, studies in the area are few and primarily with genistein. This study investigated the effects of formononetin and its synthetic analogue, 2-heptyl-formononetin (C7F), on lipid and cholesterol metabolism in C57BL/6J mice. The mice were fed a cholesterol-enriched diet for five weeks to induce hypercholesterolemia and were then fed either the cholesterol-enriched diet or the cholesterol-enriched diet-supplemented formononetin or C7F for three weeks. Body weight and composition, glucose homeostasis, and plasma lipids were compared. In another experiment, mice were fed the above diets for five weeks, and hepatic triglyceride accumulation and gene expression and histology of adipose tissue and liver were examined. Supplementation with C7F increased plasma HDL-cholesterol thereby increasing the plasma level of total cholesterol. Supplementation with formononetin did not affect plasma cholesterol but increased plasma triglycerides levels. Supplementation with formononetin and C7F induced hepatic steatosis. However, formononetin decreased markers of inflammation and liver injury. The development of hepatic steatosis was associated with deregulated expression of hepatic genes involved in lipid and lipoprotein metabolism. In conclusion, supplementation with formononetin and C7F to a cholesterol-enriched diet adversely affected lipid and lipoprotein metabolism in C57BL/6J mice.

AB - Consumption of isoflavones may prevent adiposity, hepatic steatosis, and dyslipidaemia. However, studies in the area are few and primarily with genistein. This study investigated the effects of formononetin and its synthetic analogue, 2-heptyl-formononetin (C7F), on lipid and cholesterol metabolism in C57BL/6J mice. The mice were fed a cholesterol-enriched diet for five weeks to induce hypercholesterolemia and were then fed either the cholesterol-enriched diet or the cholesterol-enriched diet-supplemented formononetin or C7F for three weeks. Body weight and composition, glucose homeostasis, and plasma lipids were compared. In another experiment, mice were fed the above diets for five weeks, and hepatic triglyceride accumulation and gene expression and histology of adipose tissue and liver were examined. Supplementation with C7F increased plasma HDL-cholesterol thereby increasing the plasma level of total cholesterol. Supplementation with formononetin did not affect plasma cholesterol but increased plasma triglycerides levels. Supplementation with formononetin and C7F induced hepatic steatosis. However, formononetin decreased markers of inflammation and liver injury. The development of hepatic steatosis was associated with deregulated expression of hepatic genes involved in lipid and lipoprotein metabolism. In conclusion, supplementation with formononetin and C7F to a cholesterol-enriched diet adversely affected lipid and lipoprotein metabolism in C57BL/6J mice.

U2 - 10.1155/2013/926942

DO - 10.1155/2013/926942

M3 - Journal article

C2 - 23738334

VL - 2013

JO - Journal of Biomedicine and Biotechnology

JF - Journal of Biomedicine and Biotechnology

SN - 1110-7243

M1 - 926942

ER -

ID: 49002350